Why INT2ACT?
For young enthusiastic researchers this international network with the focus also on extensive interaction between the participants will be exciting. It will hopefully result in a new generation of researchers with interest to explore this field in the future.
Dr. Thomas Frischmuth is Chief Executive Officer (CEO) and Chief Scientific Officer (CSO) at the baseclick GmbH in Neuried, Germany.
For more than 30 years, I have been active in the field of life science and medical technology as a researcher, consultant and in leading positions. My research activities range from chemical synthesis (small to large scale), chemical analysis, molecular and cell biology, biotechnological synthesis (small to large scale), medical device (heart support systems), agriculture to drug and treatment development. In total, I developed and evaluated 6 drugs pre-clinical (preclinical) and have taken 4 of them into phase I and/or II clinical evaluation studies. One drug is marketed for cancer treatment.
I studied biology and received a PhD and hablitation in Germany. After several stations in acadamia, I became an entrepreneur in life science investments. The focus was on drug development mainly in protein and RNA therapeutics. My main interest was in modifying the glycosylation pattern for cell recognition of protein drugs such as the alpha-Galactosidase und RNA oligos.
Beck et al. (2023), Trimannose-coupled antimiR-21 for macrophage-targeted inhalation treatment of acute inflammatory lung damage. Nature Communications (2023) 14:4564. Frischmuth T. is co-author. https://doi.org/10.1038/s41467-023-40185-1
Montiel et al. (2024), Synthesis and validation of clickable multimeric mannose ligands for dendritic cell targeting Journal of Carbohydrate Chemistry Volume 43, Issues 7–9, 21 November 2024, Pages 323-348. Frischmuth T. is co-author. https://doi.org/10.1080/07328303.2024.2418524